Ken Belotsky
Founder @ Negev Labs
Vienna, Austria
Ken Belotsky is a seed investor at Negev Labs in Vienna focused on Health Care and Biotechnology. Ken Belotsky is based out of Vienna and is the Founder of Negev Labs. Ken previously worked at Bright Box as a Executive Board Director. Ken Belotsky attended Columbia Business School.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Ken Belotsky invests in
Stages Ken Belotsky invests in
Countries Ken Belotsky invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Biopharma 1 (20%)
- Nutraceutical 1 (20%)
Stage
- Seed 2 (40%)
- Post-IPO Equity 2 (40%)
Country
- Canada 3 (60%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.7M / Post-IPO Equity / Jun 03, 2024 | |
|
Filament Health
|
Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.8M / Post-IPO Equity / Jul 19, 2023 | |
Betterlife Pharma
|
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage theimmune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. | $474K / Post-IPO Equity / Dec 07, 2022 | |
MycroDose Therapeutics
|
Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system,Ketamine oral mucosa delivery system. | Seed / Sep 21, 2021 | |
NanoPsy
|
NanoPsy is a company that develops nanotechnology for theranostic applications to effectively improve psychedelic drug efficacy. Our patented nano technology which, in combination with our targeted delivery and controlled dosing technology methods, will allow for an increase in solubility/absorption of these molecules. Thus a more efficaciousAPI. | $403.3K / Seed / Jun 29, 2021 |
Co-Investors
About Negev Labs
Negev Labs provides software development services that include web applications, system integration, and digital platform management. The company works on projects that support business operations, data handling, and online services through custom-built technologies. Its services cover development, maintenance, and technical implementation fordifferent types of digital systems. The company also supports clients by managing updates, functionality improvements, and system performance requirements.
Negev Labs Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ken Belotsky
Founder
|
|||
Kostia Adamsky
Co-Founder & Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ken Belotsky invest in?
Ken Belotsky invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ken Belotsky last invest?
The most recent investment recorded for Ken Belotsky closed in Jun 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
